We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New COVID-19 Mobile Testing Device Diagnoses Infection Immediately via Breath Sample Using AI

By LabMedica International staff writers
Posted on 11 Aug 2020
Scientists have developed a medical device that has the potential to allow public health professionals to immediately diagnose COVID-19 infection via breath sample and track through a mobile device without the need for saliva or blood samples.

Hoth Therapeutics, Inc. More...
(New York, NY, USA) has licensed the intellectual property rights relating to the development of the medical device from the George Washington University (GW). The device is based on nanotechnology Nanoholes using Plasmonics principles. The surface of the device is covered in a thin sheet of gold that can bind with other molecules, like those of a gas. Once the binding occurs, the wavelength of light bouncing off the surface changes, creating a different color of light. Different gases would cause different shifts in light. The results can be available quickly, and artificial intelligence programs can then classify the molecules that are bound to the surface of the device. The results, including the different classes of the molecules, can then be sent to the cloud by a mobile device, allowing the ability to track the data.

The researchers believe that the modified apparatus, which is as small as a strand of hair, can be coated with a solution designed to bind specifically to the SARS-CoV-2 virus that causes COVID-19. This design would allow the virus to bind to the surface, thereby allowing for the detection of an optical change that could immediately be sensed by phone cameras when an infected person's specimen is applied. The device would allow communities to build trackable real-time databases of infection and enable people to upload information directly to the cloud.

"These are devices that a public health professional could go out with into the field to administer point-of-care testing, either at a walk-up center or directly in the community," said Dr. Jeanne A. Jordan, PhD, a professor in Epidemiology at the GW Milken Institute School of Public Health, who was instrumental in recognizing the potential diagnostic capabilities of the technology. "They're extremely rapid—the turnaround time to having test results is within minutes, and you do the testing right there instead of having to send your sample to a large commercial laboratory with a massive backlog. That would allow these professionals to say immediately if someone needs to be quarantined, and to get the names of their contacts so they can start contact tracing."

"The immediate diagnosis and ongoing tracking of COVID-19 is a critical initiative towards mitigating the ongoing spread of COVID-19," said Mr. Robb Knie, Chief Executive Officer of Hoth. "This device which is under development would allow users to conduct widespread testing and provide instantaneous results through the administration of a breath sample and tracking through a mobile device. Securing the rights to this paradigm shifting technology in the fight against the global COVID-19 pandemic is a significant opportunity for Hoth and its shareholders. We look forward to working with the team at GW to accelerate the development of this breakthrough technology."

Related Links:

Hoth Therapeutics, Inc.


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Portable Electronic Pipette
Mini 96
New
Gold Member
Collection and Transport System
PurSafe Plus®
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.